19. Psychotropic Drugs
Tina Hinton
Department of Pharmacology, School of Medical Sciences, The University of Sydney, NSW, 2006, Australia
Phone: +61 2 9351 6208; Fax: +61 2 9351 3868; Email: tina.hinton@sydney.edu.au
Key words: depression, antidepressants, neurochemistry, tricyclic antidepressants, imipramine, monoamine oxidase inhibitors, phenelzine, moclobemide serotonin reuptake inhibitors, fluoxetine, combined serotonin and noradrenaline reuptake inhibitors, venlafaxine, psychosis, schizophrenia, typical antipsychotics, chlorpromazine, haloperidol, atypical antipsychotics, clozapine, olanzapine, fear, anxiety, benzodiazepine, diazepam, midazolam, temazepam, buspirone
Contents
19.1 Depression and Antidepressants
19.1.1 Depression
19.1.2 Neurochemistry of Depression and the Monoamine Theory
19.1.3 Antidepressant Indications and Drug Classes
19.1.4 General Considerations with the use of Antidepressants
19.1.5 Tricyclic Antidepressants
19.1.6 Monoamine Oxidase Inhibitors
19.1.7 Selective Serotonin Reuptake Inhibitors
19.1.8 Combined Serotonin and Noradrenaline Reuptake Inhibitors
19.1.9 Long Term Adaptive Changes with Antidepressants
19.2 Psychosis, Schizophrenia, and Antipsychotics
19.2.1 Psychosis and Schizophrenia
19.2.2 Neurochemistry of Psychosis and the Dopamine Theory
19.2.3 Antipsychotic Drug Indications and Drug Classes
19.2.4 Antipsychotic Mechanisms of Action
19.2.5 Typical Antipsychotics (First Generation)
19.2.6 Atypical Antipsychotics (Second Generation)
19.3 Anxiety and Anxiolytics
19.3.1 Fear, Anxiety and Anxiety Disorders
19.3.2 Neurochemistry of Anxiety
19.3.3 Anxiolytic Drug Indications and Drug Classes
19.3.4 Benzodiazepines
19.3.5 Antidepressants
19.3.6 Buspirone